Product Description
HEC 68498 is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin in clinical development at HEC Pharm for the treatment of idiopathic pulmonary fibrosis.
Mechanisms of Action: PI3K Inhibitor, MTOR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sunshine Lake Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Idiopathic Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HEC68498-P-01 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2021-02-26 |
88% |
2022-08-13 |
|
| PCD-DHEC68498-17-001 | P1 |
Completed |
Idiopathic Pulmonary Fibrosis |
2019-03-15 |
50% |
2021-05-08 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|